1. Volume 71, Issue 1, Pages 1-3 (January 2017)
Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer 
Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, Konrad Steinestel, Martin Boegemann, Andres J. Schrader, Julie Steinestel 
European Urology 
Volume 71, Issue 1, Pages 1-3 (January 2017)
DOI: /j.eururo
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1
Overview of prior and new therapies along with androgen receptor splice variant (AR-V7) to androgen receptor full length (AR-FL) ratio (%), prostate-specific antigen (PSA) response (%), and progression free survival (PFS; d) for the six AR-V7-positive patients experiencing benefit from next generation androgen deprivation therapy (ADT).
European Urology  , 1-3DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions